Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells
Open accessAbstract
Nuclear factor-κB (NF-κB) transcription factors play a key role in the pathogenesis of multiple myeloma (MM). The survival, proliferation and chemoresistance of malignant plasma cells largely rely on the activation of canonical and noncanonical NF-κB pathways. They are triggered by cancer-associated mutations or by the autocrine and paracrine production of cytokines and growth factors as well as direct interaction with cellular and noncellular components of bone marrow microenvironment (BM). In this context, NF-κB also significantly affects the activity of noncancerous cells, including mesenchymal stromal cells (MSCs), which have a critical role in disease progression. Indeed, NF-κB transcription factors are involved in inflammatory signaling that alters the functional properties of these cells to support cancer evolution. Moreover, they act as regulators and/or effectors of pathways involved in the interplay between MSCs and MM cells. The aim of this review is to analyze the role of NF-κB in this hematologic cancer, focusing on NF-κB-dependent mechanisms in tumor cells, MSCs and myeloma–mesenchymal stromal cell crosstalk.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NF-κB plays a critical role in controlling the impact that MM-MSCs have on multiple myeloma cells by encouraging MM-MSC proliferation, chemoresistance, and immune escape.
“Moreover, by encouraging MM-MSCs’ proliferation, chemoresistance, and immune escape, NF-κB (Nuclear factor Kappa B) plays a critical role in controlling the impact that MM-MSCs have on MM cells [104].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [104]
The Introduction says NF-κB regulates the effects of MM-MSCs on MM cells by promoting growth, chemoresistance and immune escape. But the growth attributed to NF-κB is that of MM cells, not proliferation of MM-MSCs; section 4.1 likewise describes MM-MSCs supporting MM cell growth. (LLM, conf=0.88)
Experimental — accuracy not yet measuredNF-κB activation mediates bone destruction in MM patients by modulating osteoclast stimulators like MIP-1α.
“Moreover, NF-κB activation mediates bone destruction in MM patients by modulating osteoclast stimulators like MIP-1α [142].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [142]
Section 4.2 (page unavailable) links NF-κB signaling to osteoclast formation and MM-related bone resorption, including regulation of the osteoclast-promoting factors RANKL and IL-6. It does not identify MIP-1α or say that NF-κB modulates it, so the specific mechanism in the claim is unsupported. (LLM, conf=0.85)
Experimental — accuracy not yet measuredThe NF-κB signaling pathway plays a pivotal role in the pathophysiology of multiple myeloma, significantly impacting the survival, proliferation, and chemoresistance of malignant plasma cells.
“Concurrently, the NF-κB signaling pathway plays a pivotal role in the pathophysiology of MM, significantly impacting the survival, proliferation, and chemoresistance of malignant PC.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [104]
NF-κB transcription factors mastermind important modifications to mesenchymal stromal cell functional properties that promote the progression of cancer, acting as effectors or regulators of pathways that control interactions between multiple myeloma cells and mesenchymal stromal cells.
“It’s interesting to note that NF-κB transcription factors also mastermind important modifications to MSC functional properties that promote the progression of cancer. They play a crucial role as effectors or regulators of pathways that control interactions between MM cells and MSCs on several levels [104].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · see citing works
NF-κB: At the Borders of Autoimmunity and Inflammation
Barnabei, L., Laplantine, E., Mbongo, W., Rieux‐Laucat, F., & Weil, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716469 · Cited by 641 · see citing works
NF-κB: blending metabolism, immunity, and inflammation
Capece, D., Verzella, D., Flati, I., Arboretto, P., Cornice, J., & Franzoso, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.07.004 · Cited by 538 · see citing works
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 362 · see citing works
Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S. C., Svaldi, M., & Rizzoli, V. (2005) · Blood · doi:10.1182/blood-2004-12-4986 · Cited by 322 · see citing works
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
de Jong, M. M. E., Kellermayer, Z., Papazian, N., Tahri, S., Hofste op Bruinink, D., Hoogenboezem, R., Sanders, M. A., van de Woestijne, P. C., Bos, P. K., Khandanpour, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00931-3 · Cited by 250 · see citing works
Mirzaei, S., Saghari, S., Bassiri, F., Raesi, R., Zarrabi, A., Hushmandi, K., Sethi, G., & Tergaonkar, V. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30759 · Cited by 243 · see citing works
Tai, Y., Li, X., Breitkreutz, I., Song, W., Neri, P. E., Catley, L. P., Podar, K., Hideshima, T., Chauhan, D., Raje, N. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0190 · Cited by 237 · see citing works
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works
Terpos, E., Zamagni, E., Lentzsch, S., Drake, M. T., García‐Sánz, R., Abildgaard, N., Ntanasis‐Stathopoulos, I., Schjesvold, F. H., de la Rubia, J., Kyriakou, C. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30559-3 · Cited by 220 · see citing works
Small Molecule NF-κB Pathway Inhibitors in Clinic
Ramadass, V., Vaiyapuri, T., & Tergaonkar, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145164 · Cited by 214 · see citing works
Inhibitory feedback control of NF-κB signalling in health and disease
Prescott, J. A., Mitchell, J. P., & Cook, S. J. (2021) · Biochemical Journal · doi:10.1042/bcj20210139 · Cited by 193 · see citing works
Faict, S., Muller, J., Veirman, K. D., Bruyne, E. D., Maes, K., Vrancken, L., Heusschen, R., Raeve, H. D., Schots, R., Vanderkerken, K., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0139-7 · Cited by 155 · see citing works
Jimi, E., Takakura, N., Hiura, F., Nakamura, I., & Hirata‐Tsuchiya, S. (2019) · Cells · doi:10.3390/cells8121636 · Cited by 142 · see citing works
Co-evolution of tumor and immune cells during progression of multiple myeloma
Liu, R., Gao, Q., Foltz, S. M., Fowles, J. S., Yao, L., Wang, J. T., Cao, S., Sun, H., Wendl, M. C., Sethuraman, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22804-x · Cited by 132 · see citing works
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123 · see citing works
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Swamydas, M., Murphy, E. V., Ignatz-Hoover, J. J., Malek, E., & Driscoll, J. J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01234-2 · Cited by 117 · see citing works
CD155: A Multi-Functional Molecule in Tumor Progression
Molfetta, R., Zitti, B., Lecce, M., Milito, N. D., Stabile, H., Fionda, C., Cippitelli, M., Gismondi, A., Santoni, A., & Paolini, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030922 · Cited by 113 · see citing works
Self-citationMesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Xu, S., Veirman, K. D., Becker, A. D., Vanderkerken, K., & Riet, I. V. (2018) · Leukemia · doi:10.1038/s41375-018-0061-9 · Cited by 111 · see citing works
P53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa
Carrà, G., Lingua, M. F., Maffeo, B., Taulli, R., & Morotti, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03524-9 · Cited by 109 · see citing works
NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms
Yu, L., Li, L., Medeiros, L. J., & Young, K. H. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.10.001 · Cited by 105 · see citing works
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Rizq, O., Mimura, N., Oshima, M., Saraya, A., Koide, S., Kato, Y., Aoyama, K., Nakajima-Takagi, Y., Wang, C., Chiba, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2735 · Cited by 83 · see citing works
TAM Receptor Inhibition–Implications for Cancer and the Immune System
Aehnlich, P., Powell, R., Peeters, M. J. W., Rahbech, A., & Straten, P. T. (2021) · Cancers · doi:10.3390/cancers13061195 · Cited by 81 · see citing works
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Balaji, S., Ahmed, M., Lorence, E., Yan, F., Nomie, K. J., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0621-5 · Cited by 77 · see citing works
Smoldering multiple myeloma current treatment algorithms
Rajkumar, S. V., Kumar, S. K., Lonial, S., & Mateos, M. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00719-0 · Cited by 76 · see citing works
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
Pazina, T., Macfarlane, A. W., Bernabei, L. L., Dulaimi, E., Kotcher, R. E., Yam, C., Bezman, N., Robbins, M. D. H., Ross, E. A., Campbell, K. S., et al. (2021) · Cancers · doi:10.3390/cancers13020226 · Cited by 73 · see citing works
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70 · see citing works
Zahoor, M., Westhrin, M., Aass, K. R., Moen, S. H., Misund, K., Psonka-Antonczyk, K. M., Giliberto, M., Buene, G., Sundan, A., Waage, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010801 · Cited by 69 · see citing works
Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
Ria, R., & Vacca, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020613 · Cited by 65 · see citing works
Vulpis, E., Loconte, L., Peri, A., Molfetta, R., Caracciolo, G., Masuelli, L., Tomaipitinca, L., Peruzzi, G., Petillo, S., Petrucci, M. T., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12176 · Cited by 63 · see citing works
Self-citationVallabhapurapu, S., Noothi, S. K., Pullum, D. A., Lawrie, C. H., Pallapati, R. R., Potluri, V., Kuntzen, C., Khan, S., Plas, D. R., Orlowski, R. Z., et al. (2015) · Nature Communications · doi:10.1038/ncomms9428 · Cited by 61 · see citing works
Giallongo, C., Tibullo, D., Camiolo, G., Parrinello, N. L., Romano, A., Puglisi, F., Barbato, A., Conticello, C., Lupo, G., Anfuso, C. D., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1959-5 · Cited by 55 · see citing works
Liu, Z., Liu, H., Li, Y., Shao, Q., Chen, J., Song, J., & Fu, R. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001010 · Cited by 55 · see citing works
Tsalikis, J., Abdel‐Nour, M., Farahvash, A., Sorbara, M. T., Poon, S., Philpott, D. J., & Girardin, S. E. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00489-18 · Cited by 53 · see citing works
MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
Zingoni, A., Vulpis, E., Cecere, F., Amendola, M. G., Fuerst, D., Saribekyan, T., Achour, A., Sandalova, T., Nardone, I., Peri, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00926 · Cited by 50 · see citing works
Self-citationMaiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48 · see citing works
Epigenetic Aberrations in Multiple Myeloma
Caprio, C., Sacco, A., Giustini, V., & Roccaro, A. M. (2020) · Cancers · doi:10.3390/cancers12102996 · Cited by 48 · see citing works
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger, J. S., Batalla, I. B., Weinhold, N., Meißner, T., Wroblewski, M., Janning, M., Riecken, K., Binder, M., Atanackovic, D., Taipaleenmäki, H., et al. (2014) · Leukemia · doi:10.1038/leu.2014.236 · Cited by 47 · see citing works
Desantis, V., Savino, F. D., Scaringella, A., Potenza, M. A., Nacci, C., Frassanito, M. A., Vacca, A., & Montagnani, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092513 · Cited by 45 · see citing works
Chen, T., Moscvin, M., & Bianchi, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.608815 · Cited by 44 · see citing works
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
Zitti, B., Molfetta, R., Fionda, C., Quatrini, L., Stabile, H., Lecce, M., de Turris, V., Ricciardi, M. R., Petrucci, M. T., Cippitelli, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10403-0 · Cited by 44 · see citing works
Self-citationGiallongo, C., Tibullo, D., Puglisi, F., Barbato, A., Vicario, N., Cambria, D., Parrinello, N. L., Romano, A., Conticello, C., Forte, S., et al. (2020) · Cancers · doi:10.3390/cancers12081999 · Cited by 43 · see citing works
Fairfield, H., Costa, S., Falank, C., Farrell, M., Murphy, C. S., D’Amico, A., Driscoll, H., & Reagan, M. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584683 · Cited by 42 · see citing works
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42 · see citing works
Dabbah, M., Attar‐Schneider, O., Matalon, S. T., Shefler, I., Dolberg, O. J., Lishner, M., & Drucker, L. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx045 · Cited by 41 · see citing works
Tsubaki, M., Takeda, T., Tomonari, Y., Koumoto, Y., Imano, M., Satou, T., & Nishida, S. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0114-8 · Cited by 41 · see citing works
Takeda, T., Tsubaki, M., Tomonari, Y., Kawashima, K., Itoh, T., Imano, M., Satou, T., & Nishida, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.019 · Cited by 37 · see citing works
Schinke, C., Qu, P., Mehdi, S. J., Hoering, A., Epstein, J., Johnson, S., van Rhee, F., Zangari, M., Thanendrarajan, S., Barlogie, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2627 · Cited by 35 · see citing works
Eskandani, R., Kazempour, M., Farahzadi, R., Sanaat, Z., Eskandani, M., Adibkia, K., Vandghanooni, S., & Mokhtarzadeh, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113932 · Cited by 35 · see citing works
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
Teramachi, J., Tenshin, H., Hiasa, M., Oda, A., Bat‐Erdene, A., Harada, T., Nakamura, S., Ashtar, M., Shimizu, S., Iwasa, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.234476 · Cited by 35 · see citing works
Furukawa, M., Ohkawara, H., Ogawa, K., Ikeda, K., Ueda, K., Shichishima-Nakamura, A., Ito, E., Imai, J.-I., Yanagisawa, Y., Honma, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.733030 · Cited by 34 · see citing works
Translating the anti-myeloma activity of Natural Killer cells into clinical application
Fionda, C., Stabile, H., Molfetta, R., Soriani, A., Bernardini, G., Zingoni, A., Gismondi, A., Paolini, R., Cippitelli, M., & Santoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.005 · Cited by 34 · see citing works
Self-citationIndirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma
Yu, Z., Wei, X., Liu, L., Sun, H., Fang, T., Wang, L., Li, Y., Sui, W., Wang, K., He, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103950 · Cited by 33 · see citing works
Mekhloufi, A., Kosta, A., Stabile, H., Molfetta, R., Zingoni, A., Soriani, A., Cippitelli, M., Paolini, R., Gismondi, A., Ricciardi, M. R., et al. (2020) · Cancers · doi:10.3390/cancers12020440 · Cited by 32 · see citing works
Self-citationYan, S., Vandewalle, N., Beule, N. D., Faict, S., Maes, K., Bruyne, E. D., Menu, E., Vanderkerken, K., & Veirman, K. D. (2019) · Cancers · doi:10.3390/cancers11111727 · Cited by 32 · see citing works
Vulpis, E., Stabile, H., Soriani, A., Fionda, C., Petrucci, M. T., Mariggiò, E., Ricciardi, M. R., Cippitelli, M., Gismondi, A., Santoni, A., et al. (2018) · Cancers · doi:10.3390/cancers10120473 · Cited by 32 · see citing works
Self-citationBagratuni, T., Sklirou, A., Kastritis, E., Liacos, C., Spilioti, C., Eleutherakis-Papaiakovou, E., Kanellias, N., Gavriatopoulou, M., Terpos, E., Trougakos, I., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39672-7 · Cited by 31 · see citing works
BAFF is involved in macrophage-induced bortezomib resistance in myeloma
Chen, J., He, D., Chen, Q., Guo, X., Yang, L., Lin, X., Li, Y., Wu, W., Yang, Y., He, J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.533 · Cited by 30 · see citing works
Li, X., Chen, M., Wan, Y., Zhong, L., Han, X., Chen, X., Xiao, F., Liu, J., Zhang, Y., Zhu, D., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1065 · Cited by 30 · see citing works
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
Zhou, L., Zhang, Y., Leng, Y., Dai, Y., Kmieciak, M., Kramer, L. B., Sharma, K., Wang, Y., Craun, W., & Grant, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0713-x · Cited by 29 · see citing works
Drug targets and resistance mechanisms in multiple myeloma
Naß, J., & Efferth, T. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.04 · Cited by 28 · see citing works
Fernando, R. C., Mazzotti, D. R., de Azevedo, H. F. Z., Sandes, A. F., Rizzatti, E. G., de Oliveira, M. B., Alves, V. L. F., Eugênio, A. I. P., de Carvalho, F., Dalboni, M. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38314-8 · Cited by 28 · see citing works
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 27 · see citing works
Muraoka, H., Yoshimura, C., Kawabata, R., Tsuji, S., Hashimoto, A., Ochiiwa, H., Nakagawa, F., Fujioka, Y., Matsuo, K., & Ohkubo, S. (2019) · Cancer Science · doi:10.1111/cas.14209 · Cited by 27 · see citing works
DKK1 activates noncanonical NF-κB signaling via IL-6–induced CKAP4 receptor in multiple myeloma
Li, X., Wang, J., Zhu, S., Zheng, J.-X., Xie, Y., Jiang, H., Guo, J. R., Wang, Y., Peng, Z., Wang, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004315 · Cited by 26 · see citing works
Alameda, D., Sáez, B., Lara‐Astiaso, D., Sarvide, S., Lasa, M., Alignani, D., Rodríguez, I., Gárate, S., Vilas‐Zornoza, A., Paiva, B., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.235135 · Cited by 24 · see citing works
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Ismail, N. H., Mussa, A., Zakaria, N. A., Al-Khreisat, M. J., Zahidin, M. A., Ramli, N. N., Mohammad, S. N. N. A., Hassan, R., Mohd Noor, N. H., Iberahim, S., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112767 · Cited by 22 · see citing works
Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects
Chen, H., Li, M., Sanchez, E., Wang, C. S., Lee, T. L., Soof, C. M., Casas, C. E., Cao, J., Xie, C., Udd, K. A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0293 · Cited by 22 · see citing works
Liu, Z., Deng, L., Jia, Y., Liu, H., Ding, K., Wang, W., Zhang, H., & Fu, R. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.861 · Cited by 20 · see citing works
El‐Mesery, M., Rosenthal, T., Rauert‐Wunderlich, H., Schreder, M., Stühmer, T., Leich, E., Schlösser, A., Ehrenschwender, M., Wajant, H., & Siegmund, D. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1860-2 · Cited by 20 · see citing works
Xu, S., & Lam, K. (2020) · Cancers · doi:10.3390/cancers12041045 · Cited by 19 · see citing works
Tornatore, L., Capece, D., D’Andrea, D., Begalli, F., Verzella, D., Bennett, J., Acton, G. D., Campbell, E. A., Kelly, J., Tarbit, M. H., et al. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.04.006 · Cited by 18 · see citing works
Choi, H., Kim, Y., Kang, D., Kwon, A., Kim, J., Kim, J. M., Park, S., Kim, Y., Min, C., & Kim, M. (2020) · Cell Proliferation · doi:10.1111/cpr.12819 · Cited by 18 · see citing works
Zhou, L., Zhang, Y., Meads, M. B., Dai, Y., Ning, Y., Hu, X., Li, L., Sharma, K., Nkwocha, J., Parker, R. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003597 · Cited by 16 · see citing works
Mark, C., Warrick, J. W., Callander, N. S., Hematti, P., & Miyamoto, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0941 · Cited by 15 · see citing works
Clinical proof of concept for a safe and effective NF ‐κB‐targeting strategy in multiple myeloma
Tornatore, L., Capece, D., D’Andrea, D., Begalli, F., Verzella, D., Bennett, J., Acton, G. D., Campbell, E. A., Kelly, J., Tarbit, M. H., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15569 · Cited by 15 · see citing works
Lath, D., Buckle, C., Evans, H., Fisher, M., Down, J. M., Lawson, M. A., & Chantry, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199517 · Cited by 14 · see citing works
The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells
Tsubaki, M., Seki, S., Takeda, T., Chihara, A., Arai, Y., Morii, Y., Imano, M., Satou, T., Shimomura, K., & Nishida, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217905 · Cited by 14 · see citing works
Pathogenic signaling in multiple myeloma
Bolomsky, A., & Young, R. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.005 · Cited by 13 · see citing works
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma
Miao, Y. R., Thakkar, K. N., Cenik, C., Jiang, D., Mizuno, K., Jia, C., Li, C. G., Zhao, H., Diep, A. N., Xu, Y., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220214 · Cited by 11 · see citing works
Lemaitre, L., Hamaïdia, M., Descamps, J.-G., Souto, L. D., Joubert, M.-V., Gadelorge, M., Avet‐Loiseau, H., Justo, A., Reina, N., Deschaseaux, F., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003704 · Cited by 10 · see citing works
GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells
Kosta, A., Mekhloufi, A., Lucantonio, L., Zingoni, A., Soriani, A., Cippitelli, M., Gismondi, A., Fazio, F., Petrucci, M. T., Santoni, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942640 · Cited by 9 · see citing works
Self-citationMazzera, L., Abeltino, M., Lombardi, G., Cantoni, A. M., Ria, R., Ricca, M., Saltarella, I., Naponelli, V., Rizzi, F., Perris, R., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.208280 · Cited by 7 · see citing works
Bariana, M., Cassella, E., Rateshwar, J., Ouk, S., Liou, H., Heller, C. J., Colorado, I., Feinman, R., Makhdoom, A., Siegel, D. S. D., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0257 · Cited by 7 · see citing works
Tsubaki, M., Takeda, T., Matsuda, T., Kishimoto, K., Tanaka, R., Tsurushima, K., Ishizaka, T., & Nishida, S. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00951-9 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works
Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies
Jorge, J., Neves, J. F. B. P., Alves, R., Geraldes, C., Gonçalves, A. C., & Sarmento‐Ribeiro, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119167 · Cited by 32 · see citing works
Wu, D., Tian, S., & Zhu, W. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2225767 · Cited by 28 · see citing works
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
“Moreover, by encouraging MM-MSCs’ proliferation, che-moresistance, and immune escape, NF-κB (Nuclear factor Kappa B) plays a critical role in controlling the impact that MM-MSCs have on MM cells [104].”
Chung, I., Huang, W., Huang, Y.-T., Chen, M.-L., Tsai, A.-W., Wu, P.-Y., & Yuan, T.-T. T. (2023) · Oncology Reports · doi:10.3892/or.2023.8642 · Cited by 20 · see citing works
Taheri, M., Tehrani, H. A., Dehghani, S., Rajabzadeh, A., Alibolandi, M., Zamani, N., Arefian, E., & Ramezani, M. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.01.004 · Cited by 16 · see citing works
Autophagy-related mechanisms for treatment of multiple myeloma
Kozalak, G., & Koşar, A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.108 · Cited by 14 · see citing works
Chronic Pain and Bone-Related Pathologies: A Narrative Review
Pickering, M., DeLay, M., & Morel, V. (2024) · Journal of Pain Research · doi:10.2147/jpr.s469229 · Cited by 14 · see citing works
Breaking Barriers: The Role of the Bone Marrow Microenvironment in Multiple Myeloma Progression
Agafonova, A., Prinzi, C., Salinaro, A. T., Ledda, C., Cosentino, A., Cambria, M. T., Anfuso, C. D., & Lupo, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157301 · Cited by 13 · see citing works
Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy
Zhao, X., Ming, X., Wu, J., Zhu, X., & Xiao, Y. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11011-6 · Cited by 7 · see citing works
Raf-kinase inhibitor protein (RKIP): A therapeutic target in colon cancer
Kumari, S., Peela, S., Bramhachari, P. V., Mallikarjuna, K., Nagaraju, G. P., & Srilatha, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189387 · Cited by 6 · see citing works
TIGIT/PVR axis regulates anti-tumor immunity in hematologic malignancies
Meng, F., Xiang, M., Liu, Y., & Zeng, D. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06304-2 · Cited by 4 · see citing works
Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
Maleknia, S., Benam, S. R., Ahmann, G. J., Fonseca, R., Jelinek, D. F., & Shahbazi, R. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01362-1 · Cited by 4 · see citing works
PPFIBP1 activates NF-κB signaling to enhance chemoresistance of multiple myeloma
Deng, Y., Chen, L., Zhang, Q., & Xu, Y. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101765 · Cited by 3 · see citing works
Zhang, Z., Fu, J., Li, H., Li, H., Wu, B., Tian, X., Li, M., Dai, Y., Shen, Z., Jia, J., et al. (2025) · Environmental Research · doi:10.1016/j.envres.2025.123171 · Cited by 2 · see citing works
Naiebi, R., Abroun, S., Atashi, A., Shafiee, L., Akbari, M., Maleki, M. H., & Siri, M. (2024) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-024-00962-0 · Cited by 2 · see citing works
Reduced elastin in multiple myeloma niche promotes cell proliferation
Zoabi, M., Orbuch, E., Komemi, O., Jarchowsky-Dolberg, O., Brin, Y. S., Tartakover‐Matalon, S., Pasmanik‐Chor, M., Lishner, M., & Drucker, L. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114395 · Cited by 1 · see citing works
Kumari, K., Verma, K., Sahu, M., Dwivedi, J., Paliwal, S., & Sharma, S. K. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107473 · Cited by 1 · see citing works
Anti-myeloma mechanisms of the selective NF-κB inhibitor QNZ
Cholujová, D., Valuskova, Z., Buríková, M., Hucko, M., Beke, G., Sedláčková, E., Kľúčár, Ľ., Suroviakova, K., Grofova, G., Sedlák, J., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201267 · Cited by 1 · see citing works
Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma
Pucci, M., Costanzo, E., Marfia, M., Seidita, G., Fontana, S., Corrado, C., & Alessandro, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146276 · Cited by 1 · see citing works
Inflammatory Factors and Immune Cells in Relation to Multiple Myeloma
Huang, M., Zeng, Q., Chen, D., Yang, C., Yang, Y., Zhou, M., Zhang, F.-L., Bian, Q.-H., & Yang, X. (2025) · Acta Haematologica · doi:10.1159/000543429
Enhancing oncolytic reovirus therapy with proteasome inhibitors in multiple myeloma
Aleem, M. R., Baloch, K., Shahid, M., & Talha, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003256
NPM1 mediated up – regulation of CXCR4 might drive bortezomib resistance in multiple Myeloma
Shi, Y., Deng, Y., Ma, J., Li, Y., Ji, T., Tao, H., Wang, C., & Yu, L. (2025) · Hematology · doi:10.1080/16078454.2025.2565956
Şimşek, F. M., Sevin, S., & Arslan, Y. E. (2026) · Materials Research Express · doi:10.1088/2053-1591/ae79fd
Huang, W.-H., Ismail, M. T. S., & Peng, C. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07192-w
Kakoo, A., Mohammad, D. K., Yassin, A., Rasheed, T. K., & Al-Attar, M. S. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080761
Ma, Z., Pang, X., Cui, W., & Zhang, W. (2026) · International Journal of Pharmacology · doi:10.31083/ijp50583
- Authors
- Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Lucantonio, L., Gismondi, A., Santoni, A., & Fionda, C.
- Affiliations
- Sapienza University of Rome (IT)
- Istituto Neurologico Mediterraneo (IT)
- Corresponding author
- Cippitelli, Marco
- Fionda, Cinzia
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-01-17
- Volume
- 24
- Issue
- 3
- Pages
- 1823
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9916119
- OpenAlex
- W4317103854
- Cited by
- 26
- References
- 85
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 5 · 2023: 5
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Sapienza University of Rome (2018/RG11816426E8448B, 2020/RP120172A7CD4ACB, 2017NTK4HY_005)
- Ministero dell’Istruzione, dell’Università e Ricerca Scientifica (2018/RG11816426E8448B, 2020/RP120172A7CD4ACB, 2017NTK4HY_005)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- NF-κB signaling, multiple myeloma, mesenchymal stem cells, bone marrow microenvironment, canonical NF-κB pathway, non-canonical NF-κB signaling, chemoresistance, plasma cell survival, inflammation, cytokines
- MeSH terms
- Humans, Multiple Myeloma, Transcription Factors, Signal Transduction, NF-kappa B, Stromal Cells, Tumor Microenvironment, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
